Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations
The Journal of Allergy and Clinical Immunology Nov 04, 2017
Vargas-Hernandez A, et al. - In a study sample of patients with Signal Transducer and Activator of Transcription (STAT)1 gain of function (GOF) mutations, researchers assessed the function of natural Killer (NK) cell. They concluded that properly regulated STAT1 signaling is critical for NK cell maturation and function. In this patient population, modulation of elevated STAT1 phosphorylation with ruxolitinib is an important option for therapeutic intervention.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries